Keytruda (pembrolizumab) is a prescription medication used to treat various types of cancer. It works by blocking a protein called PD-1, which helps the immune system to fight cancer cells [2].

According to the drugpatentwatch.com, Keytruda is approved for the treatment of several types of cancer, including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, microsatellite instability-high cancer, gastric cancer, cervical cancer, and hepatocellular carcinoma [1].

However, it is important to note that the approval of Keytruda for different types of cancer may vary depending on the country and the regulatory agency. For instance, in the United States, the Food and Drug Administration (FDA) has approved Keytruda for the treatment of several types of cancer, including those mentioned above [2].

In conclusion, Keytruda is approved for the treatment of various types of cancer, but the specific approvals may vary depending on the country and regulatory agency. Patients should consult with their healthcare providers to determine if Keytruda is an appropriate treatment option for their specific cancer type.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/KEYTRUDA
[2] https://www.keytruda.com/
[3] https://www.cancer.gov/publications/dictionaries/cancer-terms/def/keytruda